Drug Inotuzumab Ozogamicin Helps 'Bridge' Leukemia Patients to Curative Treatment

The ability of drug inotuzumab ozogamicin to increase the number of acute lymphoblastic leukemia patients able to bridge to stem cell transplant is encouraging.

A statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants in a randomized Phase III study of the drug inotuzumab ozogamicin.

Inotuzumab ozogamicin, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells. Once the drug connects to CD22, the ALL cell draws it inside and dies.

Haploidentical Bone Marrow Transplant Saves a Two-Year-Old With Leukemia
A haploidentical bone marrow transplant is a form of bone marrow transplant, where the doctors prefer a 50% match between the patient and donor.

‘Given that stem cell transplant is considered the only curative treatment option for patients with acute lymphoblastic leukemia, the ability of inotuzumab ozogamicin to increase the number of patients able to bridge to transplant is encouraging.’

The study, which revealed complete remission rates of nearly 81 percent and significantly longer progression-free and higher overall survival rates than with standard therapies, was conducted at The University of Texas MD Anderson Cancer Center. Study findings were reported in the June 12 online issue of the New England Journal of Medicine.

"Forty-one percent of ALL patients in the study were able to proceed to transplant after receiving inotuzumab ozogamicin compared with the 11 percent we have seen qualify through standard chemotherapy," said Hagop Kantarjian, M.D., chair of Leukemia. "Given that stem cell transplant is considered the only curative treatment option, the ability of inotuzumab ozogamicin to increase the number of patients able to bridge to transplant is encouraging."

Donor stem cell transplants generally are considered curative for this aggressive form of leukemia with more than 6,500 American adults expected to be diagnosed with the disease in 2016. However, patients must be in complete remission before they are eligible for transplant.

Personalized Chemotherapy for Leukemia Patients to Reduce Toxicity
Patients of Asian ancestry have poor tolerance to drugs used to treat acute lymphoblastic leukemia while it is commonly used in Europe and the U.S.

Current therapies for adults with newly diagnosed B-cell ALL result in complete remission rates (CR) of 60 to 90 percent. However, many of those patients will relapse and only about 30 to 50 percent will achieve long-term, disease-free survival lasting more than three years.

"Standard chemotherapy regimens result in complete remission in 31 to 41 percent of patients who relapse earlier, and just 18 to 25 percent in those who relapse later," said Kantarjian. "Patients in the inotuzumab ozogamicin study had remission rates of 58 percent, higher than previously reported, possibly due to patients being treated later in the disease course."

Immunotherapy Leads to Remission in Advanced Leukemia Patients
The immune system is well-known for its remarkable ability to locate, recognize and attack invaders like the common cold.

The study reported moderate side effects, the most common being cytopenia, a disorder that reduces blood cell production, and liver toxicity. Funding was provided by Pfizer, Inc.

Source-Eurekalert

Genetic Study Uncovers 11 Subtypes of Acute Myeloid Leukemia
Acute Myeloid Leukemia has at least 11 different diseases, and that genetic changes explain differences in survival among young patients with the condition.